Skip to main content
Praluent price to be lowered for US payers
3/12/2018

Sanofi and Regeneron have vowed to reduce the net price to US payers of Praluent, or alirocumab, after the drug, in combination with maximally tolerated statins, showed a significant decrease in cardiovascular events in high-risk patients during a clinical trial. "We hope that our unprecedented approach to collaborating with payers and other stakeholders demonstrates that it is possible to bring major innovation to patients at a price that aligns with the value delivered," said Regeneron President and Chief Executive Leonard Schleifer.

Full Story: